Month: October 2026

Highlights (All comparisons are to the prior year period unless otherwise noted):

• Net sales of $561.7 million for the quarter, up 3.3%
• Diluted earnings per share (“EPS”) of $1.98, down 20%
• Adjusted diluted EPS* of $2.08, down 21%
• Generated $64.6 million of cash from operating activities; repurchased $15 million of shares
• Updates its full-year guidance for 2026

COLMAR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) — Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM), a leading supplier in the motor vehicle aftermarket industry, today announced its financial results for the third quarter ended September 26, 2026.

Kevin Olsen, Dorman’s Chairman, President, and Chief Executive Officer, stated, “We delivered solid performance in the quarter. Net sales increased 3%, with top-line growth across each of our three business segments driven by new products and business wins. Diluted EPS was $1.98, and adjusted diluted EPS was $2.08, compared to $2.48 and $2.62, respectively, in the prior-year period. The year-over-year earnings comparison reflects the timing of tariff-related pricing that benefitted the third quarter of 2025. We also generated $65 million of operating cash flow and repurchased $15 million of our common stock in the quarter, bringing year-to-date share repurchases to a company record of $112 million.

“Given our performance through the first nine months of the year and additional pricing actions we expect to take in the fourth quarter, we are narrowing our full-year 2026 guidance. We now expect full-year net sales growth to be in the range of 2% to 3%, diluted EPS in the range of $7.95 to $8.15, and adjusted diluted EPS in the range of $8.50 to $8.70.

“Supported by our strong balance sheet and liquidity position, and the strategic advantages of our innovation engine and diversified supplier network, we remain confident in our long-term growth strategy.”

Third Quarter Financial Results
The Company reported third quarter 2026 net sales of $561.7 million, up 3.3% from net sales of $543.7 million in the third quarter of 2025.

Gross profit was $221.6 million in the third quarter of 2026, or 39.4% of net sales, compared to $241.4 million, or 44.4% of net sales, in the same quarter last year. Adjusted gross profit* was $221.2 million, or 39.4% of net sales, in the third quarter of 2026, compared to $241.4 million, or 44.4% of net sales, in the same quarter last year.

Selling, general, and administrative (“SG&A”) expenses were $138.7 million, or 24.7% of net sales, in the third quarter of 2026, compared to $135.7 million, or 25.0% of net sales, in the same quarter last year. Adjusted SG&A expenses* were $132.4 million, or 23.6% of net sales, in the third quarter of 2026, compared to $129.9 million, or 23.9% of net sales, in the same quarter last year.

Diluted EPS was $1.98 in the third quarter of 2026, down 20% from diluted EPS of $2.48 in the same quarter last year. Adjusted diluted EPS* was $2.08 in the third quarter of 2026, down 21% compared to adjusted diluted EPS* of $2.62 in the same quarter last year.

Segment results were as follows:

	Net Sales											Segment Profit Margin
($ in millions)	Q3 2026				Q3 2025				Change			Q3 2026			Q3 2025			Change
Light Duty	$	443.7			$	430.3			3	%		18.5	%		23.7	%		-520 bps
Heavy Duty	$	66.1			$	63.0			5	%		0.0	%		4.5	%		-450 bps
Specialty Vehicle	$	51.9			$	50.4			3	%		13.1	%		12.8	%		30 bps

2026 Guidance
The Company updates its full-year 2026 guidance as detailed in the table below. The Company’s guidance includes the expected impact of tariffs enacted as of October 26, 2026. The Company’s guidance excludes the impact of potential tariff changes after October 26, 2026, future acquisitions and divestitures, and additional share repurchases.

	Updated 2026 Guidance	Prior 2026 Guidance
Net Sales Growth vs. 2025	2% – 3%	3% – 5%
Diluted EPS	$7.95 – $8.15	$7.93 – $8.23
Growth vs. 2025	20% – 23%	19% – 24%
Adjusted Diluted EPS*	$8.50 – $8.70	$8.50 – $8.80
Growth vs. 2025	(4)% – (2)%	(4)% – (1)%
Tax Rate Estimate	23.5% – 24.0%	23.5%

Conference Call and Webcast
The Company will hold a conference call and webcast for investors on Tuesday, October 27, 2026, beginning at 8:00 a.m. Eastern Time. The conference call can be accessed by telephone at (800) 420-1459 within the U.S. or +1 (203) 518-9861 outside the U.S. When prompted, enter the conference ID “DORMQ326”. A live audio webcast and accompanying presentation materials can be accessed on the Company’s website at investors.dormanproducts.com. A replay of the webcast will be made available on the website shortly after the conclusion of the call.

About Dorman Products
Dorman gives professionals, enthusiasts, and owners greater freedom to fix motor vehicles. For over 100 years, we have been driving new solutions, releasing tens of thousands of aftermarket replacement products engineered to save time and money and increase convenience and reliability.

Founded and headquartered in the United States, we are a pioneering global organization offering an always-evolving catalog of products covering cars, trucks, and specialty vehicles, from chassis to body, from underhood to undercarriage, and from hardware to complex electronics.

*Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains Non-GAAP financial measures. The supplemental schedules attached include the reasons we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these Non-GAAP measures.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “likely,” “probably,” “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “views,” “estimates,” and similar expressions are used to identify these forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date such statements were made. Such forward-looking statements are based on current expectations that involve known and unknown risks, uncertainties, and other factors (many of which are outside of our control). Such risks, uncertainties and other factors relate to, among other things: competition in and the evolution of the motor vehicle aftermarket industry; changes in our relationships with, or the loss of, any customers or suppliers; our ability to develop, market and sell new and existing products; our ability to anticipate and meet customer demand; our ability to purchase necessary materials from our suppliers and the impacts of any related logistics constraints; widespread public health pandemics; political and regulatory matters, such as changes in trade policy, the imposition of tariffs and climate regulation; our ability to protect our information security systems and defend against cyberattacks; our ability to protect our intellectual property and defend against any claims of infringement; and financial and economic factors, such as our level of indebtedness, fluctuations in interest rates and inflation. More information on these risks and other potential factors that could affect the Company’s business, reputation, results of operations, financial condition, and stock price is included in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company is under no obligation to, and expressly disclaims any such obligation to, update any of the information in this document, including but not limited to any situation where any forward-looking statement later turns out to be inaccurate, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.

Investor Relations Contact
Alex Whitelam, VP, Investor Relations
awhitelam@dormanproducts.com
(445) 448-9522

Visit our Investor Relations website at investors.dormanproducts.com, which contains important Company information, including financial data and investor materials. Dorman encourages investors to visit its website periodically to view new and updated information.

DORMAN PRODUCTS, INC. Consolidated Statements of Operations (in thousands, except per-share amounts)
	Three Months Ended							Three Months Ended
(unaudited)	9/26/26				Pct.*			9/27/25				Pct. *
Net sales	$	561,722			100.0			$	543,736			100.0
Cost of goods sold		340,124			60.6				302,309			55.6
Gross profit		221,598			39.4				241,427			44.4
Selling, general, and administrative expenses		138,660			24.7				135,677			25.0
Income from operations		82,938			14.8				105,750			19.4
Interest expense		8,016			1.4				7,235			1.3
Interest income		776			0.1				28			0.0
Other income, net		1,652			0.3				1,385			0.3
Income before income taxes		77,350			13.8				99,928			18.4
Provision for income taxes		18,175			3.2				23,508			4.3
Net income	$	59,175			10.5			$	76,420			14.1
Diluted earnings per share	$	1.98						$	2.48
Weighted average diluted shares outstanding		29,860							30,782
	Nine Months Ended							Nine Months Ended
(unaudited)	9/26/26				Pct.*			9/27/25				Pct. *
Net sales	$	1,635,090			100.0			$	1,592,387			100.0
Cost of goods sold		972,112			59.5				923,739			58.0
Gross profit		662,978			40.5				668,648			42.0
Selling, general, and administrative expenses		405,040			24.8				400,343			25.1
Income from operations		257,938			15.8				268,305			16.8
Interest expense		20,685			1.3				21,862			1.4
Interest income		1,327			0.1				115			0.0
Other income, net		10,475			0.6				4,290			0.3
Income before income taxes		249,055			15.2				250,848			15.8
Provision for income taxes		58,558			3.6				58,214			3.7
Net income	$	190,497			11.7			$	192,634			12.1
Diluted earnings per share	$	6.33						$	6.26
Weighted average diluted shares outstanding		30,088							30,757

* Percentage of sales. Data may not add due to rounding.

DORMAN PRODUCTS, INC. Consolidated Balance Sheets (in thousands, except share data)
(unaudited)	9/26/26				12/31/25
Assets
Current assets:
Cash and cash equivalents	$	167,005			$	49,436
Accounts receivable, less allowance for doubtful accounts of $1,993 and $1,948		628,402				479,252
Inventories		787,358				959,019
Prepaids and other current assets		40,661				33,819
Total current assets		1,623,426				1,521,526
Property, plant, and equipment, net		165,365				168,777
Operating lease right-of-use assets		99,938				112,805
Goodwill		387,334				387,334
Intangible assets, net		241,367				257,079
Other assets		41,414				45,557
Total assets	$	2,558,844			$	2,493,078
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	180,169			$	185,125
Accrued compensation		26,182				30,756
Accrued customer rebates and returns		182,560				197,398
Current portion of long-term debt		—				37,500
Other accrued liabilities		55,659				42,048
Total current liabilities		444,570				492,827
Long-term debt		440,717				402,413
Long-term operating lease liabilities		82,685				96,568
Deferred tax liabilities		4,215				3,977
Other long-term liabilities		21,709				20,218
Commitments and contingencies
Shareholders’ equity:
Common stock, $0.01 par value; 50,000,000 shares authorized; 29,574,883 and 30,391,955 shares issued and outstanding in 2026 and 2025, respectively		296				304
Additional paid-in capital		148,857				137,109
Retained earnings		1,420,768				1,344,183
Accumulated other comprehensive loss		(4,973	)			(4,521	)
Total shareholders’ equity		1,564,948				1,477,075
Total liabilities and shareholders’ equity	$	2,558,844			$	2,493,078

Selected Cash Flow Information (unaudited):
	Three Months Ended								Nine Months Ended
(in thousands)	9/26/26				9/27/25				9/26/26				9/27/25
Cash provided by operating activities	$	64,566			$	12,205			$	260,947			$	71,990
Depreciation and amortization	$	13,765			$	14,036			$	41,672			$	41,798
Capital expenditures	$	7,683			$	10,383			$	25,208			$	29,818

DORMAN PRODUCTS, INC. Non-GAAP Financial Measures (in thousands, except per-share amounts)

Our financial results include certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). Non-GAAP financial measures should not be used as a substitute for GAAP measures, or considered in isolation, for the purpose of analyzing our operating performance, financial position or cash flows. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, we have presented these non-GAAP financial measures because we believe this presentation, when reconciled to the corresponding GAAP measure, provides useful information to investors by offering additional ways of viewing our results, profitability trends, and underlying growth relative to prior and future periods and to our peers. Management uses these non-GAAP financial measures in making financial, operating, and planning decisions and in evaluating our performance. Non-GAAP financial measures may reflect adjustments for charges such as fair value adjustments, amortization, transaction costs, severance, accelerated depreciation, and other similar expenses related to acquisitions as well as other items that we believe are not related to our ongoing performance.

Adjusted Net Income:
	Three Months Ended								Nine Months Ended
(unaudited)	9/26/26				9/27/25				9/26/26				9/27/25
Net income (GAAP)	$	59,175			$	76,420			$	190,497			$	192,634
Pretax acquisition-related intangible assets amortization [1]		5,069				5,442				15,416				16,319
Pretax acquisition-related transaction and other costs [2]		(55	)			286				420				1,119
Pretax facility consolidation costs [3]		826				—				826				—
Pretax bargain purchase gain [4]		(1,457	)			—				(1,457	)			—
Pretax write-off of capitalized debt issuance costs [5]		—				—				802				—
Pretax reduction in workforce costs [6]		—				—				—				147
Tax adjustment (related to above items) [7]		(1,393	)			(1,391	)			(4,147	)			(4,268	)
Adjusted net income (Non-GAAP)	$	62,165			$	80,757			$	202,357			$	205,951
Diluted earnings per share (GAAP)	$	1.98			$	2.48			$	6.33			$	6.26
Pretax acquisition-related intangible assets amortization [1]		0.17				0.18				0.51				0.53
Pretax acquisition-related transaction and other costs [2]		(0.00	)			0.01				0.01				0.04
Pretax facility consolidation costs [3]		0.03				—				0.03				—
Pretax bargain purchase gain [4]		(0.05	)			—				(0.05	)			—
Pretax write-off of capitalized debt issuance costs [5]		—				—				0.03				—
Pretax reduction in workforce costs [6]		—				—				—				0.00
Tax adjustment (related to above items) [7]		(0.05	)			(0.05	)			(0.14	)			(0.14	)
Adjusted diluted earnings per share (Non-GAAP)*	$	2.08			$	2.62			$	6.73			$	6.70
Weighted average diluted shares outstanding		29,860				30,782				30,088				30,757

* Amounts may not add due to rounding.
See accompanying notes at the end of this supplemental schedule.

Adjusted Gross Profit:
	Three Months Ended							Three Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
Gross profit (GAAP)	$	221,598			39.4			$	241,427			44.4
Pretax acquisition-related transaction and other costs [2]		(408	)		(0.1	)			—			—
Adjusted gross profit (Non-GAAP)	$	221,190			39.4			$	241,427			44.4
Net sales	$	561,722						$	543,736
	Nine Months Ended							Nine Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
Gross profit (GAAP)	$	662,978			40.5			$	668,648			42.0
Pretax acquisition-related transaction and other costs [2]		(408	)		(0.0	)			—			—
Adjusted gross profit (Non-GAAP)	$	662,570			40.5			$	668,648			42.0
Net sales	$	1,635,090						$	1,592,387

Adjusted SG&A Expenses:
	Three Months Ended							Three Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
SG&A expenses (GAAP)	$	138,660			24.7			$	135,677			25.0
Pretax acquisition-related intangible assets amortization [1]		(5,069	)		(0.9	)			(5,442	)		(1.0	)
Pretax acquisition-related transaction and other costs [2]		(353	)		(0.1	)			(286	)		(0.1	)
Pretax facility consolidation costs [3]		(826	)		(0.1	)			—			—
Adjusted SG&A expenses (Non-GAAP)	$	132,412			23.6			$	129,949			23.9
Net sales	$	561,722						$	543,736
	Nine Months Ended							Nine Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
SG&A expenses (GAAP)	$	405,040			24.8			$	400,343			25.1
Pretax acquisition-related intangible assets amortization [1]		(15,416	)		(0.9	)			(16,319	)		(1.0	)
Pretax acquisition-related transaction and other costs [2]		(828	)		(0.1	)			(1,119	)		(0.1	)
Pretax facility consolidation costs [3]		(826	)		(0.1	)			—			—
Pretax reduction in workforce costs [6]		—			—				(147	)		(0.0	)
Adjusted SG&A expenses (Non-GAAP)	$	387,970			23.7			$	382,758			24.0
Net sales	$	1,635,090						$	1,592,387

Adjusted Other Income, Net:
	Three Months Ended							Three Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
Other income, net (GAAP)	$	1,652			0.3			$	1,385			0.3
Pretax bargain purchase gain [4]		(1,457	)		(0.3	)			—			—
Adjusted other income, net (Non-GAAP)	$	195			0.0			$	1,385			0.3
Net sales	$	561,722						$	543,736
	Nine Months Ended							Nine Months Ended
(unaudited)	9/26/26				Pct.**			9/27/25				Pct.**
Other income, net (GAAP)	$	10,475			0.6			$	4,290			0.3
Pretax bargain purchase gain [4]		(1,457	)		(0.1	)			—			—
Pretax write-off of capitalized debt issuance costs [5]		802			0.0				—			—
Adjusted other income, net (Non-GAAP)	$	9,820			0.6			$	4,290			0.3
Net sales	$	1,635,090						$	1,592,387

* *Percentage of sales. Data may not add due to rounding.

[1] – Pretax acquisition-related intangible asset amortization results from allocating the purchase price of an acquisition to the acquired tangible and intangible assets of the acquired business and recognizing the cost of the intangible asset over the period of benefit. Such costs were $5.1 million pretax (or $3.9 million after tax) and $15.4 million pretax (or $11.8 million after tax) during the three and nine months ended September 26, 2026, respectively. Such costs were $5.4 million pretax (or $4.1 million after tax) and $16.3 million pretax (or $12.3 million after tax) during the three and nine months ended September 27, 2025, respectively.

[2] – Pretax acquisition-related transaction and other costs include costs incurred to complete and integrate acquisitions and inventory fair value adjustments. During the three and nine months ended September 26, 2026, we incurred benefits included in cost of goods sold for acquisition-related reserve releases, net of inventory fair value adjustments of $0.4 million pretax (or $0.3 million after tax). During the three and nine months ended September 26, 2026, we incurred charges included in selling, general, and administrative expenses to complete and integrate acquisitions of $0.4 million pretax (or $0.3 million after tax) and $0.8 million pretax (or $0.6 million after tax), respectively.

Pretax acquisition-related transaction and other costs include costs incurred to complete and integrate acquisitions included in selling, general, and administrative expenses totaled $0.3 million pretax (or $0.2 million after tax) and $1.1 million pretax (or $0.8 million after tax), during the three and nine months ended September 27, 2025, respectively.

[3] – Pretax facility consolidation expenses represent costs incurred in connection with our planned facility consolidations and relocations. During the three and nine months ended September 26, 2026, such costs were $0.8 million pretax (or $0.6 million after tax).

[4] – Pretax bargain purchase gain resulted from the excess fair value of assets acquired in a business combination over the purchase price and was $1.5 million pretax (or $1.5 million after tax) during the three and nine months ended September 26, 2026, and was included in other income, net.

[5] – Pretax write-off of capitalized debt issuance costs totaled $0.8 million (or $0.6 million after tax) during the nine months ended September 26, 2026. These write-offs are associated with retirement of our term loan debt and the modification of our revolving credit facility.

[6] – Pretax reduction in workforce costs represents costs incurred in connection with our planned workforce reduction, including insurance continuation costs. During the nine months ended September 27, 2025, the expenses were $0.1 million pretax (or $0.1 million after tax).

[7] – Tax adjustments represent the aggregate tax effect of all non-GAAP adjustments reflected in the table above and totaled $(1.4) million and $(4.1) million during the three and nine months ended September 26, 2026, respectively, and $(1.4) million and $(4.3) million during the three and nine months ended September 27, 2025, respectively. Such items are estimated by applying our statutory tax rate to the pretax amount, or an actual tax amount for discrete items.

2026 Guidance:

The Company updates the following guidance ranges related to its full year 2026 outlook:

	Year Ending 12/31/2026
(unaudited)	Low End				High End
Diluted earnings per share (GAAP)	$	7.95			$	8.15
Pretax acquisition-related intangible assets amortization		0.68				0.68
Pretax acquisition-related transaction and other costs		0.04				0.04
Pretax facility consolidation costs		0.03				0.03
Pretax bargain purchase gain		(0.05	)			(0.05	)
Pretax write-off of capitalized debt issuance costs		0.03				0.03
Tax adjustment (related to above items)		(0.18	)			(0.18	)
Adjusted diluted earnings per share (Non-GAAP)	$	8.50			$	8.70
Weighted average diluted shares outstanding		30,000				30,000

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Limited (“Xanadu“) (NASDAQ: XNDU) (TSX: XNDU), a leading photonic quantum computing company, today announced that the company will release its third quarter 2026 financial results on November 11th, 2026, after the financial markets close.

Xanadu will host a conference call the same day at 5:30 PM EST to discuss the results and business outlook. The call will be available live via webcast here or on the company’s website here. The call will also be accessible by telephone at 1-800-715-9871 (USA toll-free) or +1 (646) 307-1963 (USA/International toll). Participants should reference passcode 8617572 and ask to be joined into the Xanadu Quantum Technologies Ltd. (Nasdaq/TSX: XNDU) call.

An archive of the webcast will be available on the company’s website here shortly after the call.

About Xanadu

Founded in 2016, Xanadu is a Canadian photonic quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Xanadu is building fault-tolerant quantum computers using light, with systems designed to compute at room temperature. Xanadu develops both hardware and software, including  PennyLane, its open-source quantum computing platform. Xanadu is the first pure-play photonic quantum computing company to list on public markets (Nasdaq/TSX: XNDU) and is recognized globally for its breakthroughs in scalable quantum technologies. Visit xanadu.ai or follow on X @XanaduAI.

Contacts

Press Contact:
press@xanadu.ai

Investor Relations:
investors@xanadu.ai

The report shares evidence and outcomes from across Canada’s largest pharmacy network and reinforces commitment to leading health and pharmacy responsibly

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Today, Shoppers Drug Mart released its inaugural Health Outcomes Report, bringing together evidence and outcomes from across its pharmacy network to demonstrate how pharmacists and pharmacy-led programs are helping Canadians access timely care, supporting earlier disease detection, and contributing to chronic disease management.

The report reflects Shoppers Drug Mart’s commitment to lead health and pharmacy responsibly and to its purpose, Care for Canada. It also aims to contribute evidence to the broader conversation about how community pharmacy can support patients and complement Canada’s healthcare system as governments continue to enable pharmacists to practice at the top of their education and expertise.

“We believe leadership in healthcare comes with a responsibility to measure our impact, share what we are learning, and continue raising the standard of care,” says Gregers Wedell-Wedellsborg, President, Shoppers Drug Mart. “Pharmacists have an important role to play, but strengthening healthcare in Canada requires all of us to work together. By keeping patients at the centre and building stronger connections across the health system, we can help make care more accessible, coordinated, and resilient.”

Supporting care in communities across Canada

Many Canadians experience challenges accessing timely primary care, while family physicians, nurse practitioners, and other healthcare professionals are working to meet growing and increasingly complex patient needs. The role of pharmacists continues to evolve across the country, creating more opportunities to support patients and making care more accessible and timely.

Pharmacists can have an even greater impact on the health of their patients when they complement and connect with the work of physicians, nurse practitioners, and patients’ broader primary care teams, and we are seeing the positive impact their expanded role is having on the health of Canadians.

Positive health outcomes, by the numbers

The Health Outcomes Report examines the positive impact of care provided across Shoppers Drug Mart’s network of pharmacies. Some highlights include:

• Shoppers Drug Mart pharmacists provided over 1.7 million consultations and treatments for minor ailments in 2025.
• Over 85% of minor ailment assessment appointments in 2025 were booked for the same or next day.
• Over a third of services provided in Pharmacy Care Clinics in 2026 were delivered outside regular weekday hours, including evenings, weekends, and holidays.
• 95% of patients who received a minor ailment assessment for a urinary tract infection (UTI) in Ontario reported their symptoms had resolved or were improving during pharmacist follow-up calls.
• 1 in 9 patients receiving Heart Health Assessments in Alberta had A1c levels potentially indicating prediabetes or diabetes.
• 2 in 3 patients living with severe diabetes who received a medication review in Ontario had a clinically significant reduction in A1c levels within a year.
• 55% of patients referred for primary care attachment through the Pharmacy-Based Hub of Care pilot with Trillium Health Partners were successfully attached during the pilot period.

Together, the findings demonstrate areas where community pharmacy is helping patients access care closer to home, supporting earlier disease detection and contributing to the ongoing management of chronic conditions.

The report also reinforces the importance of quality, coordination and continued evaluation as the role of pharmacy evolves.

Leading health and pharmacy responsibly

Community pharmacy is one participant in a large and complex health ecosystem, and meaningful progress depends on collaboration. Shoppers Drug Mart is committed to working with governments, physicians, nurse practitioners, health system partners, patients, and others to better connect care, continuously improve quality, and understand where pharmacy can make the greatest contribution.

As part of that commitment, the Patient Care and Quality Committee of the Loblaw Board was established in 2024, bringing together leading Canadian healthcare experts to provide Loblaw independent guidance and direction helping us to continue to raise the bar for quality and innovation in patient care.

Shoppers Drug Mart is sharing the Health Outcomes Report to contribute evidence, encourage transparency and dialogue, and help inform the continued evolution of pharmacy care in Canada.

Read the full Health Outcomes Report.

About Shoppers Drug Mart Inc.

Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® affiliated stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, a Canadian provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health and other rehabilitation services, delivered through a national network of more than 400 clinics. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.

For all media inquiries, contact: pr@loblaw.ca

CINCINNATI, Oct. 26, 2026 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that it has closed on a new $350 million unsecured term loan facility. The term loan facility has a three-year term maturing on October 23, 2029 and will initially bear interest at an annual rate of SOFR plus 0.80%, with future pricing subject to adjustment based on the Company’s credit ratings and leverage ratio.

Phillips Edison Grocery Center Operating Partnership I, L.P., a subsidiary of the Company and the borrower under the term loan facility (the “Borrower”), borrowed $175 million of the term loan facility at closing with the remaining $175 million available to draw on or before April 21, 2027. The term loan also has an uncommitted accordion feature allowing the Borrower to borrow up to an additional $450 million of term loans, for total term loans of up to $800 million. The Borrower has the ability to prepay the term loan under the facility without premium or penalty any time prior to maturity.

Proceeds from the initial $175 million borrowing were used to pay down the Borrower’s outstanding $161.8 million term loan along with outstanding balances under its $1 billion revolving credit facility.

John Caulfield, Executive Vice President, CFO & Treasurer stated: “PECO continues to have one of the best balance sheets in the Shopping Center REIT sector, which positions us well for continued external growth. We appreciate the continued support of our banking partners. This attractively priced term loan extends our debt maturity profile and provides additional flexibility to match-fund our investment activity and execute our growth strategy.”

KeyBanc Capital Markets Inc. and Regions Capital Markets served as joint bookrunners. KeyBanc Capital Markets Inc.; Regions Capital Markets; BMO Bank, N.A.; Capital One, National Association; Fifth Third Bank, National Association; Mizuho Bank, Ltd.; and U.S. Bank National Association served as joint lead arrangers. KeyBank National Association served as administrative agent. Associated Bank, National Association; Banco de Sabadell, S.A.; Bank of America, N.A.; JPMorgan Chase Bank, N.A.; PNC Bank National Association; and Wells Fargo Bank, National Association also participated in the term loan.  

About Phillips Edison & Company
Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of September 30, 2026, PECO managed 328 shopping centers, including 300 wholly-owned centers comprising 33.9 million square feet across 31 states and 28 shopping centers owned in three institutional joint ventures. PECO is focused on creating great grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investors website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by the Company’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” “commit,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated, including the risk factors and other risks and uncertainties described in the Company’s 2025 Annual Report on Form 10-K, filed with the SEC on February 10, 2026, as updated from time to time in the Company’s periodic and/or current reports filed with the SEC, which are accessible on the SEC’s website at www.sec.gov. Except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:
Kimberly Green, Head of Investor Relations
(513) 692-3399, kgreen@phillipsedison.com